MAI-001 by Nanjing Minova Pharmaceutical Technology for Depression: Likelihood of Approval

MAI-001 is under clinical development by Nanjing Minova Pharmaceutical Technology and currently in Phase I for Depression.

Introducing Meteor™ chips on the IsoSpark™ platform: Advancing handsfree quantitative proteomics

We are pleased to introduce Meteor™ chips on the IsoSpark™ platform.

September 18, 2023

Hawthorne Gardening Q2 Revenue Plunges 30% Sequentially to $92.7…

ScottsMiracle-Gro Reports Fiscal 2023 Second Quarter Results U.S. Consumer First Half Sales of $1.73B in Line with Record Prior Two Years Fiscal 2Q23 GAAP EPS

May 3, 2023

Coronary Disease That Comes With a Donor Heart Does Carry Risk

Coronary artery disease (CAD) that comes with a donor heart was not uncommon and conferred cardiovascular risk, although not an early death overall, according to

August 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.